# Quanterix Corp: financial statements, quarterly QTRX · Nasdaq · CIK 1503274 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/qtrx.md) · [Financials](/companies/qtrx/financials.md) · [Filings](/companies/qtrx/filings.md) · [Insiders](/companies/qtrx/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/qtrx/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [31.6](/filings/0001503274-24-000031.md) | [31.5](/filings/0001503274-24-000025.md) | [32.1](/filings/0001503274-25-000054.md) | [34.4](/filings/0001503274-25-000091.md) | [35.8](/filings/0001503274-25-000106.md) | [35.2 d](/filings/0001503274-26-000013.md) | [30.3](/filings/0001503274-26-000021.md) | [24.5](/filings/0001503274-26-000036.md) | [40.2](/filings/0001503274-25-000106.md) | [43.9 d](/filings/0001503274-26-000013.md) | [36.4](/filings/0001503274-26-000021.md) | [32.9](/filings/0001503274-26-000036.md) | | Cost of revenue | $m | [12.2](/filings/0001503274-24-000031.md) | [12.1](/filings/0001503274-24-000025.md) | [13.5](/filings/0001503274-25-000054.md) | [12.1](/filings/0001503274-25-000091.md) | [15.7](/filings/0001503274-25-000106.md) | [13.0 d](/filings/0001503274-26-000013.md) | [15.5](/filings/0001503274-26-000021.md) | [14.5](/filings/0001503274-26-000036.md) | [23.0](/filings/0001503274-25-000106.md) | [23.8 d](/filings/0001503274-26-000013.md) | [20.8](/filings/0001503274-26-000021.md) | [20.2](/filings/0001503274-26-000036.md) | | Gross profit | $m | [19.4](/filings/0001503274-24-000031.md) | [19.4](/filings/0001503274-24-000025.md) | [18.5](/filings/0001503274-25-000054.md) | [22.2](/filings/0001503274-25-000091.md) | [20.2](/filings/0001503274-25-000106.md) | [22.2 d](/filings/0001503274-26-000013.md) | [14.8](/filings/0001503274-26-000021.md) | [10.0](/filings/0001503274-26-000036.md) | [17.2](/filings/0001503274-25-000106.md) | [20.0 d](/filings/0001503274-26-000013.md) | [15.6](/filings/0001503274-26-000021.md) | [12.7](/filings/0001503274-26-000036.md) | | Research and development | $m | [7.7](/filings/0001503274-24-000031.md) | [7.2](/filings/0001503274-24-000025.md) | [6.7](/filings/0001503274-25-000054.md) | [8.2](/filings/0001503274-25-000091.md) | [8.1](/filings/0001503274-25-000106.md) | [8.1 d](/filings/0001503274-26-000013.md) | [10.0](/filings/0001503274-26-000021.md) | [9.1](/filings/0001503274-26-000036.md) | [8.0](/filings/0001503274-25-000106.md) | [8.8 d](/filings/0001503274-26-000013.md) | [7.3](/filings/0001503274-26-000021.md) | [7.8](/filings/0001503274-26-000036.md) | | Selling, general and administrative | $m | [23.6](/filings/0001503274-24-000031.md) | [23.4](/filings/0001503274-24-000025.md) | [26.0](/filings/0001503274-25-000054.md) | [24.1](/filings/0001503274-25-000091.md) | [22.9](/filings/0001503274-25-000106.md) | [28.6 d](/filings/0001503274-26-000013.md) | [31.2](/filings/0001503274-26-000021.md) | [30.4](/filings/0001503274-26-000036.md) | [39.1](/filings/0001503274-25-000106.md) | [35.1 d](/filings/0001503274-26-000013.md) | [29.8](/filings/0001503274-26-000021.md) | [27.4](/filings/0001503274-26-000036.md) | | Operating income | $m | [(12.8)](/filings/0001503274-24-000031.md) | [(13.6)](/filings/0001503274-24-000025.md) | [(15.2)](/filings/0001503274-25-000054.md) | [(10.9)](/filings/0001503274-25-000091.md) | [(11.7)](/filings/0001503274-25-000106.md) | [(14.8) d](/filings/0001503274-26-000013.md) | [(26.4)](/filings/0001503274-26-000021.md) | [(37.1)](/filings/0001503274-26-000036.md) | [(37.3)](/filings/0001503274-25-000106.md) | [(24.8) d](/filings/0001503274-26-000013.md) | [(41.4)](/filings/0001503274-26-000021.md) | [(49.4)](/filings/0001503274-26-000036.md) | | Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Income tax | $m | [0.2](/filings/0001503274-24-000031.md) | [0.1](/filings/0001503274-24-000025.md) | [0.2](/filings/0001503274-25-000054.md) | [0.1](/filings/0001503274-25-000091.md) | [0.1](/filings/0001503274-25-000106.md) | [(0.0) d](/filings/0001503274-26-000013.md) | [(2.9)](/filings/0001503274-26-000021.md) | [(0.1)](/filings/0001503274-26-000036.md) | [(2.5)](/filings/0001503274-25-000106.md) | [0.3 d](/filings/0001503274-26-000013.md) | [(0.0)](/filings/0001503274-26-000021.md) | [(0.1)](/filings/0001503274-26-000036.md) | | Net income | $m | [(6.7)](/filings/0001503274-24-000031.md) | [(8.8)](/filings/0001503274-24-000025.md) | [(11.2)](/filings/0001503274-25-000106.md) | [(7.4)](/filings/0001503274-25-000106.md) | [(8.4)](/filings/0001503274-25-000106.md) | [(11.6) d](/filings/0001503274-26-000013.md) | [(20.5)](/filings/0001503274-26-000036.md) | [(30.0)](/filings/0001503274-26-000036.md) | [(33.5)](/filings/0001503274-25-000106.md) | [(23.1) d](/filings/0001503274-26-000013.md) | [(17.5)](/filings/0001503274-26-000036.md) | [(48.9)](/filings/0001503274-26-000036.md) | | Diluted EPS | $ per share | [(0.18)](/filings/0001503274-24-000031.md) | [(0.23)](/filings/0001503274-24-000025.md) | [(0.29)](/filings/0001503274-25-000054.md) | [(0.19)](/filings/0001503274-25-000091.md) | [(0.22)](/filings/0001503274-25-000106.md) | not reported | [(0.53)](/filings/0001503274-26-000021.md) | [(0.77)](/filings/0001503274-26-000036.md) | [(0.73)](/filings/0001503274-25-000106.md) | not reported | [(0.37)](/filings/0001503274-26-000021.md) | [(1.04)](/filings/0001503274-26-000036.md) | | Basic EPS | $ per share | [(0.18)](/filings/0001503274-24-000031.md) | [(0.23)](/filings/0001503274-24-000025.md) | [(0.29)](/filings/0001503274-25-000054.md) | [(0.19)](/filings/0001503274-25-000091.md) | [(0.22)](/filings/0001503274-25-000106.md) | not reported | [(0.53)](/filings/0001503274-26-000021.md) | [(0.77)](/filings/0001503274-26-000036.md) | [(0.73)](/filings/0001503274-25-000106.md) | not reported | [(0.37)](/filings/0001503274-26-000021.md) | [(1.04)](/filings/0001503274-26-000036.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: not reported - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [201](/filings/0001503274-24-000031.md) | [174](/filings/0001503274-25-000031.md) | [45.3](/filings/0001503274-25-000054.md) | [47.0](/filings/0001503274-25-000091.md) | [29.3](/filings/0001503274-25-000106.md) | [56.7](/filings/0001503274-26-000013.md) | [76.5](/filings/0001503274-26-000021.md) | [133](/filings/0001503274-26-000036.md) | [38.3](/filings/0001503274-25-000106.md) | [29.8](/filings/0001503274-26-000036.md) | [36.2](/filings/0001503274-26-000021.md) | [44.2](/filings/0001503274-26-000036.md) | | Current assets | $m | [382](/filings/0001503274-24-000025.md) | [382](/filings/0001503274-25-000031.md) | [369](/filings/0001503274-24-000027.md) | [370](/filings/0001503274-24-000029.md) | [367](/filings/0001503274-24-000031.md) | [364](/filings/0001503274-26-000013.md) | [335](/filings/0001503274-25-000054.md) | [322](/filings/0001503274-25-000091.md) | [233](/filings/0001503274-25-000106.md) | [212](/filings/0001503274-26-000036.md) | [186](/filings/0001503274-26-000021.md) | [171](/filings/0001503274-26-000036.md) | | Total assets | $m | [429](/filings/0001503274-24-000025.md) | [429](/filings/0001503274-25-000031.md) | [414](/filings/0001503274-24-000027.md) | [416](/filings/0001503274-24-000029.md) | [411](/filings/0001503274-24-000031.md) | [407](/filings/0001503274-26-000013.md) | [397](/filings/0001503274-25-000054.md) | [376](/filings/0001503274-25-000091.md) | [444](/filings/0001503274-25-000106.md) | [419](/filings/0001503274-26-000036.md) | [367](/filings/0001503274-26-000021.md) | [320](/filings/0001503274-26-000036.md) | | Current liabilities | $m | [35.9](/filings/0001503274-24-000025.md) | [39.0](/filings/0001503274-25-000031.md) | [32.8](/filings/0001503274-24-000027.md) | [38.1](/filings/0001503274-24-000029.md) | [36.5](/filings/0001503274-24-000031.md) | [42.0](/filings/0001503274-26-000013.md) | [40.4](/filings/0001503274-25-000054.md) | [48.2](/filings/0001503274-25-000091.md) | [77.4](/filings/0001503274-25-000106.md) | [74.8](/filings/0001503274-26-000036.md) | [49.9](/filings/0001503274-26-000021.md) | [50.4](/filings/0001503274-26-000036.md) | | Total liabilities | $m | [76.4](/filings/0001503274-24-000025.md) | [78.6](/filings/0001503274-25-000031.md) | [70.8](/filings/0001503274-24-000027.md) | [75.1](/filings/0001503274-24-000029.md) | [72.1](/filings/0001503274-24-000031.md) | [76.5](/filings/0001503274-26-000013.md) | [80.1](/filings/0001503274-25-000054.md) | [83.2](/filings/0001503274-25-000091.md) | [130](/filings/0001503274-25-000106.md) | [123](/filings/0001503274-26-000036.md) | [84.5](/filings/0001503274-26-000021.md) | [82.4](/filings/0001503274-26-000036.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [353](/filings/0001503274-24-000031.md) | [350](/filings/0001503274-26-000013.md) | [343](/filings/0001503274-25-000106.md) | [341](/filings/0001503274-25-000106.md) | [339](/filings/0001503274-25-000106.md) | [330](/filings/0001503274-26-000036.md) | [316](/filings/0001503274-26-000036.md) | [292](/filings/0001503274-26-000036.md) | [315](/filings/0001503274-25-000106.md) | [296](/filings/0001503274-26-000036.md) | [282](/filings/0001503274-26-000036.md) | [237](/filings/0001503274-26-000036.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: not reported - Current portion of debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(3.9) d](/filings/0001503274-24-000031.md) | [(6.2) d](/filings/0001503274-26-000013.md) | [(20.2)](/filings/0001503274-25-000054.md) | [(5.0) d](/filings/0001503274-25-000091.md) | [(5.7) d](/filings/0001503274-25-000106.md) | [(4.3) d](/filings/0001503274-26-000013.md) | [(13.9)](/filings/0001503274-26-000021.md) | [(5.7) d](/filings/0001503274-26-000036.md) | [(41.2) d](/filings/0001503274-25-000106.md) | [(16.4) d](/filings/0001503274-26-000013.md) | [(18.1)](/filings/0001503274-26-000021.md) | [(5.1) d](/filings/0001503274-26-000036.md) | | Capital expenditure | $m | [0.9 d](/filings/0001503274-24-000031.md) | [2.0 d](/filings/0001503274-26-000013.md) | [0.5](/filings/0001503274-25-000054.md) | [1.6 d](/filings/0001503274-25-000091.md) | [0.9 d](/filings/0001503274-25-000106.md) | [0.4 d](/filings/0001503274-26-000013.md) | [1.3](/filings/0001503274-26-000021.md) | [0.8 d](/filings/0001503274-26-000036.md) | [0.7 d](/filings/0001503274-25-000106.md) | [(0.1) d](/filings/0001503274-26-000013.md) | [0.1](/filings/0001503274-26-000021.md) | [0.1 d](/filings/0001503274-26-000036.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [37.3](/filings/0001503274-24-000027.md) | [37.5](/filings/0001503274-24-000029.md) | [37.7](/filings/0001503274-24-000031.md) | [37.9](/filings/0001503274-24-000025.md) | [38.1](/filings/0001503274-25-000054.md) | [38.3](/filings/0001503274-25-000091.md) | [38.4](/filings/0001503274-25-000106.md) | [38.7](/filings/0001503274-26-000021.md) | [38.9](/filings/0001503274-26-000036.md) | [46.1](/filings/0001503274-25-000106.md) | [47.0](/filings/0001503274-26-000021.md) | [47.2](/filings/0001503274-26-000036.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 47,293,065 at 2026-08-03, from the cover of the [10-Q filed 2026-08-10](/filings/0001503274-26-000036.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.